View Clinical Trial (Medical Research Study)
Etiological Factors of Obesity-Associated Hyperandrogenemia in Peripubertal Girls
| City: |
|
Charlottesville |
| State: |
|
Virginia |
| Zip Code: |
|
22908 |
| Conditions: |
|
Obesity - Hyperandrogenemia - Polycystic Ovary Syndrome |
| Purpose: |
|
The purpose of this study is to learn if obese pre- and early pubertal girls with
hyperandrogenemia (HA) are more insulin resistant (i.e., have lower insulin-stimulated
glucose disposal) compared to obese peripubertal girls without HA; and that overnight mean
luteinizing hormone (LH) concentration is also an independent predictor of free testosterone
concentrations, especially in mid- to late pubertal girls.
|
| Study Summary: |
|
A number of pathophysiological mechanisms underlie the polycystic ovary syndrome (PCOS).
Neuroendocrine abnormalities play a significant role in most women with PCOS, and PCOS is
associated with relative resistance of the gonadotropin releasing hormone (GnRH) pulse
generator to negative feedback by progesterone and estradiol. This hypothalamic resistance
to negative feedback appears to be a result of hyperandrogenemia (HA), and can also occur in
adolescents with HA. We have hypothesized that peripubertal HA (which can represent a
forerunner of adult PCOS) can promote the development of PCOS in part via induction of
hypothalamic resistance to negative feedback. However, the cause of peripubertal HA remains
largely unknown. Obesity is a well-recognized pathophysiological factor in the HA of adult
PCOS; and recent data demonstrate that peripubertal obesity is associated with HA. However,
the mechanisms underlying the relationship between peripubertal obesity and HA—and the
marked variability of androgen levels observed among obese girls—are unknown. We have
gathered preliminary data that suggests that obese pre- and early pubertal girls with high
androgen levels also exhibit greater degrees of insulin resistance compared to obese girls
with lower androgens.
The primary goal of this pilot project is to begin to establish the relationship between
insulin resistance (as determined by insulin clamp studies) and free testosterone
concentrations in obese peripubertal girls. Secondarily, the aim is to assess the
contributions of elevated luteinizing hormone (determined by frequent blood sampling for LH)
in obesity-associated HA across puberty.
Subjects will be admitted to the General Clinical Research Center at 1600 h after 4 hours of
fasting. We will measure luteinizing hormone every 10 minutes from 1800 h to 0900 h; other
hormones (e.g., testosterone) will be assessed as well. Measurements of insulin and glucose
will occur before and after a standardized mixed meal (eaten at 1900 h) and while fasting
the following morning. A standard hyperinsulinemic euglycemic clamp procedure will be
performed from 0900-1100 h.
Characterization of the factors underlying peripubertal HA may permit prediction of which
pre- and early pubertal girls will subsequently go on to develop symptoms of PCOS. Data
generated by this project will prompt novel future studies to investigate the complex
interactions among metabolic and classical endocrine pathways that lead to PCOS.
|
| Criteria: |
|
Inclusion Criteria:
- Peripubertal (Tanner stage 1 to 5) girl, age 8-16 years
- Obesity (BMI-for-age ≥ 95th percentile)
- Generally healthy (save for exogenous obesity)
- Ability and willingness of subject/parents to provide informed assent/consent
Exclusion Criteria:
- Age < 8 or > 16 y
- Greater than 4 y post-menarche
- Obesity associated with a diagnosed (genetic) syndrome (e.g., Prader-Willi syndrome,
leptin deficiency), obesity related to medications (e.g., glucocorticoids), etc.
- Pregnancy or lactation
- Virilization
- Total testosterone > 150 ng/dl, which suggests the possibility of a virilizing
neoplasm
- DHEAS greater than twice upper limit of age-appropriate normal range
- 17-OHP greater than 250 ng/dl, which suggests the possibility of congenital adrenal
hyperplasia (if postmenarcheal, the 17-OHP will be collected during the follicular
phase, or > 60 if oligomenorrheic) NOTE: If a 17-OHP > 250 ng/dl is confirmed on
repeat testing, an ACTH stimulation test will be offered, with a post-ACTH 17-OHP <
1000 ng/dl being required for study participation
- History of premature adrenarche (i.e., appearance of pubic and/or axillary hair
before age 8)
- Fasting glucose > 125 mg/dl or hemoglobin A1c > 7.0%
- Abnormal TSH or prolactin
- Evidence of Cushing's syndrome by history or physical exam (e.g., history of impaired
growth, striae)
- Hematocrit < 36% or hemoglobin < 12 g/dl
- Significant and current cardiac or pulmonary dysfunction (e.g., known or suspected
congestive heart failure; asthma requiring systemic intermittent corticosteroids;
etc.)
- Abnormal liver enzymes, age-specific alkaline phosphatase, or a bilirubin > 1.5 times
upper limit of normal
- Abnormal sodium, potassium, bicarbonate concentrations, or elevated creatinine
concentration
- Weight less than 34 kg is an exclusion criterion (to ensure safe blood withdrawal)
- Subjects using restricted medication (see restrictions below) are excluded unless the
subject's primary care provider approves stopping the medication
|
| NCT ID: |
|
NCT00928759 |
| Primary Contact: |
|
Principal Investigator
Christopher McCartney, MD
University of Virginia
Anne Gabel, BSc
Phone: 434-243-6911
Email: pcos@virginia.edu
|
| Backup Contact: |
|
Email: cm2hq@virginia.edu
Christopher McCartney, MD
Phone: 434-243-6911
|
| Location Contact: |
|
Charlottesville, Virginia 22908
United States
Anne Gabel, BSc
Phone: 434-243-6911
Email: pcos@virginia.edu
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|